Ignite Creation Date:
2024-05-05 @ 12:08 PM
Last Modification Date:
2024-10-26 @ 9:21 AM
Study NCT ID:
NCT00257322
Status:
COMPLETED
Last Update Posted:
2018-10-31
First Post:
2005-11-18
Brief Title:
Cellular Immune Augmentation in Colon and Rectal Cancer
Sponsor:
University of California Irvine
Organization:
University of California Irvine
Study Overview
Official Title:
A Pilot Study of Cellular Immune Augmentation in Colon and Rectal Cancer Therapy
Status:
COMPLETED
Status Verified Date:
2018-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
While new treatments for metastatic and recurrent colorectal cancer have become available over the past several years this disease remains incurable with a limited life expectancy from the time of diagnosis New strategies for treatment of disseminated colorectal cancer are needed Under this proposal patients with advanced colorectal cancer will receive Granulocyte-Macrophage Colony-Stimulating Factor GM-CSF to stimulate endogenous dendritic cells and enhance anti-tumor immune mechanisms This will be combined with standard chemotherapy and patients will be followed for response and overall survival Detailed correlative laboratory analysis will also be performed to define the extent of dendritic cell and cellular immune system stimulation
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2003-2876 | OTHER | University of California Irvine | None |